Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy (BRAVE)

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT06524375
Trial Phases:	Phase II	Protocol IDs:
Eligibility:	, Male and Female	Study Type:	Treatment
Study Sponsor:	Genentech, Inc.
NCI Full Details:	https://clinicaltrials.gov/study/NCT06524375

Summary

The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease [uMRD < or 10^-4 in peripheral blood (PB)] by end of combination treatment (EOCT) to allow off-treatment period.

The acronym BRAVE stands for Btki Responders to Achieve deep remission (or off-treatment periods) with VEnetoclax.

Treatment Sites in Georgia

University Cancer and Blood Center, LLC - Athens Medical Oncology
3320 Old Jefferson Road
Building 800
Athens, GA 30607
www.universitycancer.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.